A detailed history of Darwin Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Darwin Advisors, LLC holds 925 shares of CRSP stock, worth $44,289. This represents 0.01% of its overall portfolio holdings.

Number of Shares
925
Holding current value
$44,289
% of portfolio
0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$44.62 - $62.75 $41,273 - $58,043
925 New
925 $43,000
Q2 2020

Aug 06, 2020

SELL
$38.5 - $76.05 $16,362 - $32,321
-425 Closed
0 $0
Q1 2020

May 01, 2020

BUY
$33.68 - $62.53 $14,314 - $26,575
425 New
425 $18,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Darwin Advisors, LLC Portfolio

Follow Darwin Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Darwin Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Darwin Advisors, LLC with notifications on news.